Servier and Neurochlore have recently announced that, following a lack of efficacy in two Phase III trials of bumetanide for autism spectrum disorder (ASD) in adolescents, they would be terminating […]
Bumetanide
Trending topics and news from the Bumetanide category
Back to news home